By: Benzinga
January 22, 2013 at 13:47 PM EST
UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts
Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) from Hold to Buy and announced a $67.00 price target. Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here